# Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

> **NCT00660673** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 262 (actual)

## Conditions studied

- Advanced Parkinson's Disease

## Interventions

- **DRUG:** Levodopa-Carbidopa Intestinal Gel (LCIG)
- **DEVICE:** CADD-Legacy® 1400 ambulatory infusion pump
- **DEVICE:** Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)

## Key facts

- **NCT ID:** NCT00660673
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11-13
- **Primary completion:** 2021-11-30
- **Final completion:** 2021-11-30
- **Target enrollment:** 262 (ACTUAL)
- **Last updated:** 2022-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00660673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00660673, "Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00660673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*